Today Ryght AI announced its clinical research platform is now available in the Microsoft Azure Marketplace, allowing healthcare organizations to deploy the software on Azure, pay for it through consolidated billing, and apply existing Azure commit dollars. The company positions the move as a practical way to speed adoption of AI in study startup and trial operations without adding another standalone vendor to legal and procurement workflows.
At the core of Ryght’s approach is a network of “AI Site Twins”, dynamic digital models of clinical research sites worldwide that capture operational characteristics, trial history, staff capabilities, and historic enrollment performance. Sponsors and CROs use that data inside Ryght’s workflow tools to automate site identification and feasibility, rank sites by likely enrollment success, and optimize execution across study hubs. The company says the platform supports generative and agentic AI features to summarize, reason across documents, and route tasks.
The pitch is straightforward: faster, more defensible decisions on where to run a trial, and fewer hand-offs between spreadsheets, emails, and legacy systems. Ryght highlights a SOC 2 Type II architecture and real-time collaboration between sponsors, CROs, and sites as table stakes for enterprise buyers in regulated environments.
“Making our platform available through Microsoft Azure Marketplace represents a significant step forward in making AI-powered clinical research tools more accessible to the organizations that need them most,” said Simon Arkell, Ryght CEO and Co-Founder. “By leveraging Azure’s robust cloud infrastructure and marketplace ecosystem, we’re removing barriers that have traditionally slowed the adoption of innovative clinical trial technologies.”
Why this could move the needle
-
Procurement reality: Many health systems and sponsors now prefer marketplace transactions for security review, metering, and budget control. Being purchasable via Azure can shorten sales cycles.
-
Data model differentiation: If Site Twins prove accurate at predicting enrollment performance, they address one of trial operations’ costliest risks: opening sites that don’t enroll.
-
Operational fit: Consolidating communication and tasking among sponsors, CROs, and sites inside one system can reduce latency between feasibility decisions and first-patient-in.
“Microsoft Azure Marketplace welcomes Ryght, which joins a cloud marketplace landscape offering flexibility and economic value while transacting tens of billions of dollars a year in revenues,” said Jake Zborowski, General Manager, Microsoft Azure Platform at Microsoft Corp. “Thanks to Azure Marketplace and partners like Ryght, customers can do more with less by increasing efficiency, buying confidently, and spending smarter.”
What to watch
-
Evidence: Case studies showing faster site activation, higher screen-to-randomization rates, or fewer underperforming sites will matter more than AI branding.
-
Integrations: Depth of connections to CTMS/EDC, safety, and document systems will determine day-to-day usefulness.
-
Governance: Ongoing audits and controls around model outputs (explainability, bias, versioning) will be scrutinized by compliance teams.
Bottom line: Marketplace availability doesn’t guarantee outcomes, but it removes real friction in how hospitals, sponsors, and CROs buy software. If Ryght’s Site Twin approach consistently steers trials to the right sites and automates the boring parts of feasibility, the Azure listing gives it a credible route into large, Azure-standardized organizations.
Organizations can use Ryght now for Biopharma and CRO applications now at their respective links.
